Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
Add more filters










Publication year range
1.
Nutr Neurosci ; 27(2): 106-119, 2024 Feb.
Article in English | MEDLINE | ID: mdl-36634108

ABSTRACT

The hypothalamus controls food intake by integrating nutrient signals, of which one of the most important is glucose. Consequently, impairments in hypothalamic glucose-sensing mechanisms are associated with hyperphagia and obesity. Environmental enrichment (EE) is an animal housing protocol that provides complex sensory, motor, and social stimulations and has been proven to reduce adiposity in laboratory mice. However, the mechanism by which EE promotes adiposity-suppressing effect remains incompletely understood. Neurotrophic factors play an important role in the development and maintenance of the nervous system, but they are also involved in the hypothalamic regulation of feeding. Brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) are expressed in the hypothalamus and their expression is stimulated by glucose. EE is associated with increased expression of Bdnf mRNA in the hypothalamus. Therefore, we hypothesized that EE potentiates the anorectic action of glucose by altering the expression of neurotrophic factor genes in the hypothalamus. Male C57BL/6 mice were maintained under standard or EE conditions to investigate the feeding response to glucose and the associated expression of feeding-related neurotrophic factor genes in the hypothalamus. Intraperitoneal glucose injection reduced food intake in both control and EE mice with a significantly greater reduction in the EE group compared to the control group. EE caused a significantly enhanced response of Gdnf mRNA expression to glucose without altering basal Gdnf mRNA expression and Bdnf mRNA response to glucose. These findings suggest that EE enhances glucose-induced feeding suppression, at least partly, by enhancing hypothalamic glucose-sensing ability that involves GDNF.


Subject(s)
Brain-Derived Neurotrophic Factor , Glucose , Animals , Male , Mice , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Gene Expression , Glial Cell Line-Derived Neurotrophic Factor/genetics , Glial Cell Line-Derived Neurotrophic Factor/metabolism , Glial Cell Line-Derived Neurotrophic Factor/pharmacology , Glucose/metabolism , Hypothalamus/metabolism , Mice, Inbred C57BL , Obesity/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism
2.
Neuroreport ; 33(13): 583-589, 2022 09 07.
Article in English | MEDLINE | ID: mdl-36049163

ABSTRACT

Brain-derived neurotrophic factor (BDNF) is expressed in both hypothalamic neurons and microglia, and plays a critical role in the regulation of metabolism. Although hypothalamic expression of BDNF is regulated by metabolic signals such as nutrients and hormones, it remains unknown whether these signals differentially regulate BDNF expression in different cell types. The present study aimed to determine whether glucose and fructose regulate BDNF expression in microglia via the specific glucose transporter. To determine the effect of glucose and fructose on Bdnf mRNA and protein expression, murine microglial cell line SIM-A9 cells were exposed to the maintenance concentration of glucose (17.5 mmol/l), high glucose (25 mmol/l), or fructose (7.5 mmol/l) for 40 min to 24 h. To determine whether the blockade of glucose transporter 5 (GLUT5) negates the effect of glucose on Bdnf mRNA expression, cells were exposed to 25 mmol/l glucose in the presence or absence of the GLUT5 inhibitor for 4 h. Levels of Bdnf mRNA and protein were measured by real-time PCR and ELISA, respectively. High glucose caused a significant increase in both pan-Bdnf and long-form Bdnf (L-Bdnf) mRNA as well as protein levels when compared with the maintenance of concentration of glucose in a time-dependent manner. Fructose treatment also increased L-Bdnf mRNA expression. Pharmacological blockade of GLUT5 did not affect glucose-induced Bdnf mRNA expression. These findings suggest that glucose and fructose directly stimulate Bdnf mRNA expression in microglia and these responses may mediate the metabolic actions of glucose and fructose.


Subject(s)
Brain-Derived Neurotrophic Factor , Fructose , Glucose , Microglia , Animals , Brain-Derived Neurotrophic Factor/metabolism , Fructose/metabolism , Fructose/pharmacology , Gene Expression , Glucose/metabolism , Glucose/pharmacology , Glucose Transport Proteins, Facilitative/pharmacology , Mice , Microglia/metabolism , RNA, Messenger/metabolism
3.
Behav Brain Res ; 433: 113986, 2022 09 05.
Article in English | MEDLINE | ID: mdl-35798208

ABSTRACT

Social and environmental factors influence behavior via modulation of brain physiological functions. Environmental enrichment (EE) is an animal housing technique that provides complex sensory, motor, and social stimulation, leading to modifications in the innate aggressiveness in group-housed laboratory mice. Brain-derived neurotrophic factor (BDNF) is encoded by multiple splice variants and plays a critical role in controlling aggressive behavior in a transcript variant-specific manner. BDNF mediates the beneficial effects of EE on a variety of pathophysiological conditions. These findings led to the hypothesis that EE reduces aggressive behavior by altering the expression of Bdnf mRNA in a transcript variant-specific manner. To test this hypothesis, 3-4-week-old male C57BL/6 mice were randomly group-housed (5 mice per cage) under standard or EE conditions for 6-8 weeks. Aggressive behavior was monitored and levels of Bdnf mRNA variants in aggression-related brain regions were measured. Mice housed in EE cages displayed a significantly lower frequency of aggressive interactions compared to control mice. EE increased levels of Bdnf mRNA variant I (Bdnf I) in the amygdala while it reduced levels of Bdnf I in the hypothalamus, hippocampus, prefrontal cortex, parietal cortex, and brainstem. Meanwhile, EE did not significantly alter levels of Bdnf mRNA variants IIc, IV, and VI in all brain regions examined. These findings support the hypothesis that EE diminishes inter-male aggression by altering Bdnf mRNA expression in a transcript variant-specific and brain region-specific manner. Specifically, brain region-specific alterations in Bdnf I expression may partly mediate EE-induced suppression of inter-male aggression.


Subject(s)
Brain-Derived Neurotrophic Factor , Environment , Aggression/physiology , Animals , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Hippocampus/metabolism , Male , Mice , Mice, Inbred C57BL , RNA, Messenger/metabolism
4.
Int J Mol Sci ; 23(13)2022 Jun 25.
Article in English | MEDLINE | ID: mdl-35806073

ABSTRACT

Feeding-regulating neurotrophic factors are expressed in both neurons and glial cells. However, nutritional regulation of anorexigenic glial cell line-derived neurotrophic factor (GDNF) and orexigenic mesencephalic astrocyte-derived neurotrophic factor (MANF) expression in specific cell types remains poorly understood. Hypothalamic glucose sensing plays a critical role in the regulation of food intake. It has been theorized that local glucose concentration modulates microglial activity partially via glucose transporter 5 (GLUT5). We hypothesized that an increased local glucose concentration stimulates GDNF expression while inhibiting MANF expression in the hypothalamus and microglia via GLUT5. The present study investigated the effect of glucose on Gdnf and Manf mRNA expression in the mouse hypothalamus and murine microglial cell line SIM-A9. Intracerebroventricular glucose treatment significantly increased Gdnf mRNA levels in the hypothalamus without altering Manf mRNA levels. Exposure to high glucose caused a significant increase in Gdnf mRNA expression and a time-dependent change in Manf mRNA expression in SIM-A9 cells. GLUT5 inhibitor treatment did not block glucose-induced Gdnf mRNA expression in these cells. These findings suggest that microglia are responsive to changes in the local glucose concentration and increased local glucose availability stimulates the expression of microglial GNDF through a GLUT5-independent mechanism, contributing to glucose-induced feeding suppression.


Subject(s)
Glial Cell Line-Derived Neurotrophic Factor , Microglia , Animals , Gene Expression , Glial Cell Line-Derived Neurotrophic Factor/metabolism , Glucose/metabolism , Glucose/pharmacology , Glucose Transporter Type 5/metabolism , Mice , Microglia/metabolism , Nerve Growth Factors/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism
5.
Int J Mol Sci ; 22(23)2021 Nov 23.
Article in English | MEDLINE | ID: mdl-34884473

ABSTRACT

Microglia play a role in the regulation of metabolism and pathogenesis of obesity. Microglial activity is altered in response to changes in diet and the body's metabolic state. Solute carrier family 2 member 5 (Slc2a5) that encodes glucose transporter 5 (GLUT5) is a fructose transporter primarily expressed in microglia within the central nervous system. However, little is known about the nutritional regulation of Slc2a5 expression in microglia and its role in the regulation of metabolism. The present study aimed to address the hypothesis that nutrients affect microglial activity by altering the expression of glucose transporter genes. Murine microglial cell line SIM-A9 cells and primary microglia from mouse brain were exposed to different concentrations of glucose and levels of microglial activation markers and glucose transporter genes were measured. High concentration of glucose increased levels of the immediate-early gene product c-Fos, a marker of cell activation, Slc2a5 mRNA, and pro-inflammatory cytokine genes in microglial cells in a time-dependent manner, while fructose failed to cause these changes. Glucose-induced changes in pro-inflammatory gene expression were partially attenuated in SIM-A9 cells treated with the GLUT5 inhibitor. These findings suggest that an increase in local glucose availability leads to the activation of microglia by controlling their carbohydrate sensing mechanism through both GLUT5-dependent and -independent mechanisms.


Subject(s)
Glucose Transporter Type 5/genetics , Glucose/pharmacology , Microglia/cytology , Animals , Cells, Cultured , Gene Expression Regulation/drug effects , Mice , Microglia/drug effects , Microglia/metabolism , Proto-Oncogene Proteins c-fos/genetics
6.
Nutrients ; 10(11)2018 Nov 01.
Article in English | MEDLINE | ID: mdl-30388740

ABSTRACT

Common genetic variants of the fat mass and obesity associated (FTO) gene are strongly associated with obesity and type 2 diabetes. FTO is ubiquitously expressed. Earlier studies have focused on the role of hypothalamic FTO in the regulation of metabolism. However, recent studies suggest that expression of hepatic FTO is regulated by metabolic signals, such as nutrients and hormones, and altered FTO levels in the liver affect glucose and lipid metabolism. This review outlines recent findings on hepatic FTO in the regulation of metabolism, with particular focus on hepatic glucose and lipid metabolism. It is proposed that abnormal activity of hepatic signaling pathways involving FTO links metabolic impairments such as obesity, type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). Therefore, a better understanding of these pathways may lead to therapeutic approaches to treat these metabolic diseases by targeting hepatic FTO. The overall goal of this review is to place FTO within the context of hepatic regulation of metabolism.


Subject(s)
Alpha-Ketoglutarate-Dependent Dioxygenase FTO/genetics , Glucose/metabolism , Lipid Metabolism/genetics , Liver/metabolism , Genetic Variation , Humans
7.
Biochem Biophys Res Commun ; 498(4): 842-848, 2018 04 15.
Article in English | MEDLINE | ID: mdl-29530527

ABSTRACT

Xenin is a gastrointestinal hormone that belongs to the neurotensin family. Central administration of xenin to obese mice reduces food intake and body weight gain and causes alterations in the expression of lipid metabolism-related genes and proteins in white adipose tissue (WAT). However, it has not been tested whether or not xenin directly acts on adipose tissue and alters lipid metabolism. The present study was performed to address this possibility by examining the effect of xenin treatment on the levels of glycerol and free fatty acids (FFA) and expression levels of lipolysis marker proteins ex vivo in cultured mouse WAT. Xenin treatment significantly increased concentrations of glycerol and FFA in culture media and increased phosphorylation of hormone sensitive lipase (HSL) in ex vivo cultured WAT. These findings support the hypothesis that xenin directly acts on adipose tissues and stimulates lipolysis. Thus, enhancement of xenin action and its downstream signaling may offer a novel and effective therapy for obese patients by reducing the amount of stored fat in adipose tissue.


Subject(s)
Adipose Tissue, White/metabolism , Neurotensin/pharmacology , Adipose Tissue, White/cytology , Adipose Tissue, White/drug effects , Animals , Cells, Cultured , Culture Media/analysis , Fatty Acids, Nonesterified/metabolism , Glycerol/metabolism , Male , Mice , Mice, Inbred C57BL , Phosphorylation , Sterol Esterase/metabolism
8.
Free Radic Biol Med ; 115: 458-470, 2018 02 01.
Article in English | MEDLINE | ID: mdl-29277394

ABSTRACT

Debilitating muscle-disuse atrophy in aging or obesity has huge socioeconomic impact. Since nitric oxide (NO) mediates muscle satellite cell activation and induces hypertrophy with exercise in old mice, we tested whether treatment with the NO donor, isosorbide dinitrate (ISDN), during hind limb suspension would reduce atrophy. Mice were suspended 18 days, with or without daily ISDN (66mg/kg). Muscles were examined for atrophy (weight, fiber diameter); regulatory changes in atrogin-1 (a negative regulator of muscle mass), myostatin (inhibits myogenesis), and satellite cell proliferation; and metabolic responses in myosin heavy chains (MyHCs), liver lipid, and hypothalamic gene expression. Suspension decreased muscle weight and weight relative to body weight between 25-55%, and gastrocnemius fiber diameter vs. CONTROLS: In young-adult mice, ISDN attenuated atrophy by half or more. In quadriceps, ISDN completely prevented the suspension-induced rise in atrogin-1 and drop in myostatin precursor, and attenuated the changes in MyHCs 1 and 2b observed in unloaded muscles without treatment. Fatty liver in suspended young-adult mice was also reduced by ISDN; suspended young mice had higher hypothalamic expression of the orexigenic agouti-related protein, Agrp than controls. Notably, a suspension-induced drop in muscle satellite cell proliferation by 25-58% was completely prevented (young mice) or attenuated (halved, in young-adult mice) by ISDN. NO-donor treatment has potential to attenuate atrophy and metabolic changes, and prevent regulatory changes during disuse and offset/prevent wasting in age-related sarcopenia or space travel. Increases in precursor proliferation resulting from NO treatment would also amplify benefits of physical therapy and exercise.


Subject(s)
Aging/physiology , Hindlimb/pathology , Isosorbide Dinitrate/therapeutic use , Muscular Disorders, Atrophic/therapy , Nitric Oxide/metabolism , Sarcopenia/therapy , Satellite Cells, Skeletal Muscle/physiology , Agouti-Related Protein/metabolism , Animals , Disease Models, Animal , Female , Hindlimb/drug effects , Hindlimb Suspension , Humans , Hypothalamus/metabolism , Male , Mice , Mice, Inbred C57BL , Muscle Proteins/metabolism , Myosin Heavy Chains/metabolism , Myostatin/metabolism , SKP Cullin F-Box Protein Ligases/metabolism
9.
Neuropeptides ; 63: 67-73, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28190525

ABSTRACT

Xenin is a gastrointestinal hormone that reduces food intake when administered centrally and it has been hypothesized that central action of xenin participates in the regulation of whole-body metabolism. The present study was performed to address this hypothesis by investigating the central effect of xenin on the expression of genes and proteins that are involved in the regulation of lipid metabolism in white adipose tissue (WAT). Male obese ob/ob mice received intracerebroventricular (i.c.v.) injections of xenin (5µg) twice 12h apart. Food intake and body weight change during a 24-h period after the first injection were measured. Epididymal WAT was collected at the end of the 24-h treatment period and levels of lipid metabolism-related genes and proteins were measured. Xenin treatment caused significant reductions in food intake and body weight compared to control vehicle treatment. Levels of fatty acid synthase (FASN) protein were significantly reduced by xenin treatment, while levels of adipose triglyceride lipase (Atgl) and beta-3 adrenergic receptor (Adrb3) mRNA and phosphorylated hormone sensitive lipase (Ser660-pHSL and Ser563-pHSL) were significantly increased by xenin treatment. These findings suggest that central action of xenin causes alterations in lipid metabolism in adipose tissue toward reduced lipogenesis and increased lipolysis, possibly contributing to xenin-induced body weight reduction. Thus, enhancing central action of xenin and its downstream targets may be possible targets for the treatment of obesity by reducing the amount of stored fat in adipose tissue.


Subject(s)
Adipose Tissue, White/drug effects , Gene Expression/drug effects , Lipid Metabolism/genetics , Neurotensin/pharmacology , Obesity/genetics , Adipose Tissue, White/metabolism , Animals , Body Weight/drug effects , Eating/drug effects , Fatty Acid Synthases/genetics , Fatty Acid Synthases/metabolism , Fatty Acids, Nonesterified/blood , Glycerol/blood , Lipase/genetics , Lipase/metabolism , Male , Mice , Obesity/metabolism , Phosphorylation/drug effects , Receptors, Adrenergic, beta-3/genetics , Receptors, Adrenergic, beta-3/metabolism
10.
Life Sci ; 170: 50-55, 2017 Feb 01.
Article in English | MEDLINE | ID: mdl-27914922

ABSTRACT

AIMS: To investigate the role of glucose and insulin in the regulation of hepatic fat mass and obesity associated (Fto) gene expression and the role of hepatic Fto in the regulation of gluconeogenic gene expression. MAIN METHODS: To determine the effect of hyperglycemia on hepatic Fto expression, levels of Fto mRNA in liver were compared between normoglycemic/normoinsulinemic, hypereglycemic/hyperinsulinemic, and hyperglycemic/hypoinsulinemic mice. To determine the direct effect of insulin on Fto expression, levels of Fto, glucose-6-phosphatase (G6pase), and phosphoenolpyruvate carboxykinase (Pepck) mRNA levels were compared between control and insulin-treated mouse liver tissues cultured ex vivo and immortalized mouse hepatocytes AML12. To determine the role of Fto in the regulation of gluconeogenic gene expression, we examined the effect of enhanced Fto expression on G6pase and Pepck mRNA levels in AML12 cells. KEY FINDINGS: Fto mRNA levels were significantly reduced in hyperglycemic/hyperinsulinemic mice compared to normoglycemic/normoinsulinemic mice, while they were indistinguishable between hyperglycemic/hypoinsulinemic mice and normoglycemic/normoinsulinemic mice. Insulin treatment reduced Fto, G6pase, and Pepck mRNA levels compared to control vehicle treatment in both ex vivo cultured mouse liver tissues and AML12 cells. Enhanced Fto expression significantly increased G6pase and Pepck mRNA level in AML12 cells. SIGNIFICANCE: Our findings support the hypothesis that hepatic Fto participates in the maintenance of glucose homeostasis possibly by mediating the inhibitory effect of glucose and insulin on gluconeogenic gene expression in liver. It is further suggested that impairments in nutritional and hormonal regulation of hepatic Fto expression may lead to impairments in glycemic control in diabetes.


Subject(s)
Adipose Tissue/metabolism , Alpha-Ketoglutarate-Dependent Dioxygenase FTO/metabolism , Hyperglycemia/metabolism , Insulin/metabolism , Liver/metabolism , Obesity/metabolism , Animals , Blood Glucose/metabolism , Cell Line , Gene Expression Profiling , Gene Expression Regulation , Gluconeogenesis , Glucose/metabolism , Glucose-6-Phosphatase/metabolism , Hepatocytes/cytology , Homeostasis , Male , Mice , Mice, Inbred C57BL , Phosphoenolpyruvate Carboxykinase (ATP)/metabolism , RNA, Messenger/metabolism
11.
Behav Brain Res ; 312: 118-26, 2016 10 01.
Article in English | MEDLINE | ID: mdl-27316340

ABSTRACT

Xenin is a gut hormone that reduces food intake by partly acting through the hypothalamus via neurotensin receptor 1 (Ntsr1). However, specific signaling pathways that mediate xenin-induced feeding suppression are not fully understood. Activation of Ntsr1 leads to the activation of the extracellular signal-regulated kinase (ERK). Hypothalamic ERK participates in the regulation of food intake by mediating the effect of hormonal signals. Therefore, we hypothesized that the anorectic effect of xenin is mediated by hypothalamic ERK signaling. To address this hypothesis, we compared levels of phosphorylation of ERK1/2 (pERK1/2) in the hypothalamus of both control and xenin-treated mice. The effect of xenin on ERK1/2 phosphorylation was also examined in mouse hypothalamic neuronal cell lines with or without Ntsr1. We also examined the effect of the blockade of central ERK signaling on xenin-induced feeding suppression in mice. The intraperitoneal (i.p.) injection of xenin caused a significant increase in the number of pERK1/2-immunoreactive cells in the hypothalamic arcuate nucleus. The majority of pERK1/2-positive cells expressed neuronal nuclei (NeuN), a marker for neurons. Xenin treatment increased pERK1/2 levels in one cell line expressing Ntsr1 but not another line without Ntsr1 expression. Both i.p. and intracerebroventricular (i.c.v.) injections of xenin reduced food intake in mice. The i.c.v. pre-treatment with U0126, a selective inhibitor of ERK1/2 upstream kinases, did not affect xenin-induced reduction in food intake. These findings suggest that although xenin activates ERK signaling in subpopulations of hypothalamic neurons, xenin does not require the activation of hypothalamic ERK signaling pathway to elicit feeding suppression.


Subject(s)
Eating , Hypothalamus/metabolism , MAP Kinase Signaling System , Neurotensin/metabolism , Animals , Cell Line , Eating/drug effects , Hypothalamus/drug effects , MAP Kinase Signaling System/drug effects , Male , Mice , Mice, Inbred C57BL , Neurons/drug effects , Neurons/metabolism , Neurotensin/administration & dosage , Phosphorylation
13.
Behav Brain Res ; 261: 60-4, 2014 Mar 15.
Article in English | MEDLINE | ID: mdl-24333379

ABSTRACT

Xenin is a gut hormone that reduces food intake partly by acting through the hypothalamus. However, the mechanism of hypothalamic xenin action is not fully understood. To identify xenin-regulated genes in the hypothalamus, we compared expression levels of metabolism-related genes in the hypothalamus between saline-treated control and xenin-treated mice. Intraperitoneal injection of xenin caused a significant increase in hypothalamic interleukin 1 beta (IL-1ß) mRNA levels without causing a significant change in hypothalamic IL-1α mRNA levels. To further examine the possible contribution of IL-1 signaling to xenin's anorexigenic action, the effect of intraperitoneal injection of xenin on food intake was compared between wild-type and type I IL-1 receptor (IL-1RI)-deficient mice. Intraperitoneal administration of xenin (7.5 µg/g b.w.) caused a significant reduction of food intake in wild-type mice, while it failed to reduce food intake in pre-obese IL-1RI-deficient mice. These findings support the role of hypothalamic IL-1ß-IL-1RI signaling in the mediation of the anorexigenic effect of xenin.


Subject(s)
Cerebral Cortex/drug effects , Feeding Behavior/drug effects , Hypothalamus/drug effects , Hypothalamus/metabolism , Neurotensin/pharmacology , Receptors, Interleukin-1 Type I/deficiency , Animals , Cerebral Cortex/metabolism , Dose-Response Relationship, Drug , Eating/drug effects , Feeding Behavior/physiology , Interleukin 1 Receptor Antagonist Protein/deficiency , Interleukin 1 Receptor Antagonist Protein/genetics , Interleukin 1 Receptor Antagonist Protein/metabolism , Interleukin-1/genetics , Interleukin-1/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Microarray Analysis , RNA, Messenger/metabolism , Receptors, Interleukin-1 Type I/genetics , Signal Transduction
14.
Behav Brain Res ; 256: 512-9, 2013 Nov 01.
Article in English | MEDLINE | ID: mdl-24013028

ABSTRACT

Hypothalamic glucose sensing plays a critical role in the regulation of food intake and metabolism. Glucose injection, either centrally or peripherally suppresses food intake. However, the mechanism of glucose-induced feeding suppression is not fully understood. It has been demonstrated that hypothalamic interleukin 1 beta (IL-1ß) mRNA levels are altered by metabolic states and IL-1 signaling participates in the regulation of food intake. Therefore, we hypothesized that hypothalamic IL-1 gene expression is regulated by glucose and glucose-induced feeding suppression is mediated via hypothalamic IL-1 signaling. To address this hypothesis, we examined the effect of glucose on IL-1α and IL-1ß mRNA expression in the hypothalamus. We also examined the effect of intraperitoneal injection of glucose on food intake in wild-type and type I IL-1 receptor (IL-1RI)-deficient mice. Levels of IL-1α and IL-1ß mRNA in the hypothalamus were increased in response to feeding and intraperitoneal injection of glucose, and were positively correlated with blood glucose levels in mice. Exposure of hypothalamic explants to high glucose (10 mM) media increased IL-1α and IL-1ß mRNA levels compared to low glucose (1 mM) media. Intraperitoneal glucose administration reduced food intake in wild-type mice, while the feeding-suppressing effect of glucose was attenuated in IL-1RI-deficient mice. These findings support the role for hypothalamic IL-1 signaling in the mediation of the anorectic effect of glucose.


Subject(s)
Anorexia/metabolism , Eating/drug effects , Glucose/pharmacology , Hypothalamus/metabolism , Interleukin-1/metabolism , Signal Transduction/physiology , Animals , Anorexia/chemically induced , Hypothalamus/drug effects , Interleukin-1/genetics , Male , Mice , Mice, Inbred C57BL
15.
Life Sci ; 88(15-16): 664-9, 2011 Apr 11.
Article in English | MEDLINE | ID: mdl-21315740

ABSTRACT

AIMS: The central melanocortin system regulates a variety of metabolic functions including lipid metabolism and hepatic lipogenic gene expression. The objective of the present study was to determine whether central melanocortin regulates hepatic lipogenic gene expression under insulin insufficient condition. MAIN METHODS: We examined the effect of intracerebroventricular (i.c.v.) injection of MTII, a melanocortin agonist, on hepatic gene expression in a mouse model of the insulin-deficient diabetes. Diabetes was induced in male C57BL/6J mice by intraperitoneal injections of streptozotocin (STZ). Diabetic mice received daily i.c.v. injections of MTII (3 nmol) for 11 days. Hepatic expression levels of lipogenic genes and their transcription factors were measured. KEY FINDINGS: MTII treatment significantly reduced hepatic expression levels of genes encoding lipid biosynthetic enzymes, stearoyl-CoA desaturase 1 (SCD1), glycerol-3-phosphate acyltransferase 1 (GPAT1), acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1), and DGAT2 mRNA without significant changes in serum insulin levels, homeostasis model-assessment of insulin resistance (HOMA-IR) and glucose tolerance in STZ-induced diabetic mice. MTII treatment also reduced fatty acid synthase (FAS) and SCD1 protein levels in the liver of diabetic mice. Expression levels of genes encoding transcription factors of these lipogenic genes, sterol regulatory element-binding protein 1c (SREBP-1c) and peroxisome proliferator-activated receptor γ2 (PPARγ2) were also significantly reduced by MTII treatment. SIGNIFICANCE: These data suggest that the insulin-independent mechanism is involved in the regulation of hepatic lipogenic gene expression. Enhanced central melanocortin signaling may be effective in improving abnormal lipid metabolism associated with insulin-deficiency or insulin-insufficiency.


Subject(s)
Diabetes Mellitus, Experimental/physiopathology , Gene Expression Regulation/drug effects , Liver/drug effects , Receptors, Melanocortin/agonists , alpha-MSH/analogs & derivatives , Animals , Diabetes Mellitus, Type 1/physiopathology , Injections, Intraventricular , Insulin/blood , Lipid Metabolism/drug effects , Lipogenesis/genetics , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Receptors, Melanocortin/metabolism , Streptozocin , Transcription Factors/metabolism , alpha-MSH/administration & dosage , alpha-MSH/pharmacology
16.
Neuropeptides ; 45(2): 123-9, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21216462

ABSTRACT

Impairments in leptin-melanocortin signaling are associated with insulin-deficient diabetes and leptin treatment has been shown to be effective in reversing hyperglycemia in animal models of type 1 diabetes. Therefore, we hypothesized that enhanced central melanocortin signaling reverses the metabolic impairments associated with type 1 diabetes. To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days. STZ-induced hyperglycemia and glucose intolerance were not improved by MTII treatment. MTII treatment did not alter expression levels of genes encoding gluconeogenic enzymes including glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), in the liver of diabetic mice. Skeletal muscle and white adipose tissue glucose transporter 4 (GLUT4) mRNA levels were not altered by MTII treatment in diabetic mice. In contrast, serum nonesterified fatty acid (NEFA) levels were significantly increased in STZ-induced diabetic mice compared to non-diabetic control mice and MTII treatment significantly reduced serum NEFA levels in diabetic mice. MTII treatment also significantly reduced expression levels of hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) mRNA in white adipose tissue of diabetic mice without a significant change in serum insulin levels. Expression levels of lipoprotein lipase (LPL) and fatty acid translocase (FAT/CD36) mRNA in white adipose tissue and skeletal muscle were not changed by MTII treatment. These data suggest that central melanocortin signaling regulates lipid metabolism and that enhancing central melanocortin signaling is effective in reversing abnormal lipid metabolism, but not carbohydrate metabolism, at least partly by reducing lipolysis in type 1 diabetes.


Subject(s)
Diabetes Mellitus, Experimental/metabolism , Lipid Metabolism/drug effects , Melanocortins/agonists , alpha-MSH/analogs & derivatives , Animals , Blood Glucose/metabolism , Body Weight , Child , Eating , Humans , Insulin/blood , Leptin/blood , Male , Mice , Mice, Inbred C57BL , Triglycerides/blood , alpha-MSH/pharmacology
17.
Biochem Biophys Res Commun ; 400(4): 713-7, 2010 Oct 01.
Article in English | MEDLINE | ID: mdl-20816934

ABSTRACT

Common variants in the fat mass and obesity associated (FTO) gene are associated with obesity and type 2 diabetes. Fto-deficient mice develop hepatic insulin resistance, leading to the hypothesis that hepatic Fto plays a role in the regulation of glucose metabolism and that hepatic Fto expression is regulated by metabolic states. We found that hepatic Fto mRNA levels were increased by fasting in mice. Intraperitoneal glucose injection reduced hepatic Fto mRNA levels without significant changes in body weight in fasted mice. The inverse correlation between Fto mRNA and glucose remained significant after adjusting for body weight. There were positive correlations between hepatic Fto mRNA expression and gluconeogenic gene expression. These data support the hypothesis that hepatic Fto expression changes in response to metabolic states and glucose reduces hepatic Fto mRNA expression independently of body weight. Hepatic Fto may participate in the feedback regulation of glucose metabolism via gluconeogenesis.


Subject(s)
Blood Glucose/genetics , Gluconeogenesis/genetics , Liver/metabolism , Proteins/metabolism , RNA, Messenger/metabolism , Alpha-Ketoglutarate-Dependent Dioxygenase FTO , Animals , Body Weight/genetics , Gene Expression Regulation , Male , Mice , Mice, Inbred C57BL
18.
Neurosci Lett ; 481(1): 59-63, 2010 Aug 30.
Article in English | MEDLINE | ID: mdl-20599589

ABSTRACT

Xenin, a 25-amino acid gastrointestinal peptide, inhibits feeding by acting through the central nervous system. Gastrointestinal hormones reduce food intake partly by activating the brainstem and inhibiting gastric emptying. Therefore, we hypothesized that xenin delays gastric emptying through the activation of the brainstem cells. To address this hypothesis, we examined the effect of intraperitoneal (i.p.) injection of xenin on gastric emptying rate and brainstem Fos expression in mice. Gastric emptying rate was reduced by about 93% in xenin-treated mice compared to saline-treated control mice. The i.p. xenin injection significantly increased Fos-immunoreactive cells in the nucleus of the solitary tract (NTS) of the brainstem, but not area postrema (AP) and dorsal motor nucleus of the vagus (DMV). These findings support the hypothesis that xenin-induced anorexia is at least partly due to delayed gastric emptying and the activation of the NTS cells.


Subject(s)
Gastric Emptying/drug effects , Neurotensin/pharmacology , Solitary Nucleus/drug effects , Animals , Eating/drug effects , Food Deprivation/physiology , Gene Expression Regulation/drug effects , Male , Mice , Mice, Inbred C57BL , Oncogene Proteins v-fos/metabolism , Organ Size/drug effects , Solitary Nucleus/metabolism , Statistics, Nonparametric , Stomach/anatomy & histology
19.
Endocrinology ; 151(9): 4455-66, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20630999

ABSTRACT

Atherothrombotic cardiovascular diseases are the predominant causes of mortality of diabetic patients. Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor for fibrinolysis, and it is also implicated in inflammation and tissue remodeling. Increased levels of PAI-1 and glycated low-density lipoprotein (glyLDL) were detected in patients with diabetes. Previous studies in our laboratory demonstrated that heat shock factor-1 (HSF1) is involved in glyLDL-induced PAI-1 overproduction in vascular endothelial cells (EC). The present study investigated transmembrane signaling mechanisms involved in glyLDL-induced HSF1 and PAI-1 up-regulation in cultured human vascular EC and streptozotocin-induced diabetic mice. Receptor for advanced glycation end products (RAGE) antibody prevented glyLDL-induced increase in the abundance of PAI-1 in EC. GlyLDL significantly increased the translocation of V-Ha-Ras Harvey rat sarcoma viral oncogene homologue (H-Ras) from cytoplasm to membrane compared with LDL. Farnesyltransferase inhibitor-277 or small interference RNA against H-Ras inhibited glyLDL-induced increases in HSF1 and PAI-1 in EC. Treatment with diphenyleneiodonium, a nicotinamide adenine dinucleotide phosphate oxidase (NOX) inhibitor, blocked glyLDL-induced translocation of H-Ras, elevated abundances of HSF1 and PAI-1 in EC, and increased release of hydrogen peroxide from EC. Small interference RNA for p22(phox) prevented glyLDL-induced expression of NOX2, HSF1, and PAI-1 in EC. GlyLDL significantly increased V-raf-1 murine leukemia viral oncogene homolog 1 (Raf-1) phosphorylation. Treatment with Raf-1 inhibitor blocked glyLDL-induced increase of PAI-1 mRNA in EC. The levels of RAGE, H-Ras, NOX4, HSF1, and PAI-1 were increased in hearts of streptozotocin-diabetic mice and positively correlated with plasma glucose. The results suggest that RAGE, NOX, and H-Ras/Raf-1 are implicated in the up-regulation of HSF1 or PAI-1 in vascular EC under diabetes-associated metabolic stress.


Subject(s)
DNA-Binding Proteins/metabolism , Endothelial Cells/drug effects , Lipoproteins, LDL/pharmacology , Plasminogen Activator Inhibitor 1/metabolism , Signal Transduction/drug effects , Transcription Factors/metabolism , Animals , Antibodies/pharmacology , Blood Glucose/metabolism , Blotting, Western , Cell Line , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/metabolism , Endothelial Cells/cytology , Endothelial Cells/metabolism , Glycation End Products, Advanced , Heat Shock Transcription Factors , Humans , Male , Mice , Mice, Inbred C57BL , NADPH Oxidases/genetics , NADPH Oxidases/metabolism , Onium Compounds/pharmacology , Plasminogen Activator Inhibitor 1/genetics , Proto-Oncogene Proteins c-raf/metabolism , RNA Interference , Receptor for Advanced Glycation End Products , Receptors, Immunologic/immunology , Receptors, Immunologic/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Streptozocin , ras Proteins/metabolism
20.
Neurosci Lett ; 468(1): 64-7, 2010 Jan 01.
Article in English | MEDLINE | ID: mdl-19857548

ABSTRACT

Central administration of neuromedins and neuromedin-related peptides suppresses food intake in rodents. Neurotensin- and neuromedin U (NMU)-induced anorexia is mainly mediated through neurotensin receptor 1 (Ntsr1) and NMU receptor 2, respectively. Xenin belongs to the neurotensin family and suppresses food intake via an unknown receptor. It has been suggested that Ntsr1 also mediates biological actions of xenin and NMU. Therefore, we examined the effect of intracerebroventricular injection of xenin and NMU on food intake and body weight in wild-type and Ntsr1-deficient mice. The feeding-suppressing and weight gain-inhibiting effects of xenin were abolished in Ntsr1-deficient mice, but NMU reduced food intake and body weight gain in both wild-type and Ntsr1-deficient mice. These findings support the role for Ntsr1 in the mediation of the metabolic effect of xenin as well as neurotensin. Therefore, enhancement of signaling through the Ntsr1 receptor is a potential strategy to reduce appetite and ameliorate obesity.


Subject(s)
Eating/physiology , Neuropeptides/physiology , Neurotensin/physiology , Receptors, Neurotensin/physiology , Animals , Body Weight/drug effects , Eating/drug effects , Male , Mice , Mice, Knockout , Neuropeptides/pharmacology , Neurotensin/pharmacology , Receptors, Neurotensin/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...